Oncopeptides Ab
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 57
- Market Cap
- -
- Website
- http://www.oncopeptides.se
Clinical Trials
61
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Oncopeptides AB
- Registration Number
- NCT04918511
- Locations
- 🇨🇿
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno, Czechia
🇨🇿University Hospital Ostrava, Clinic of Hematooncology, Ostrava, Czechia
🇨🇿Charles University and General Hospital in Prague, 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Praha, Czechia
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
- Conditions
- Relapsed Multiple MyelomaRelapsed-Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 54
- Registration Number
- NCT04649060
- Locations
- 🇧🇬
University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Clinical Hematology Clinic, Plovdiv, Bulgaria
🇧🇬Specialized Hospital for Active Treatment of Hematological Diseases, Clinical Hematology Clinic, Sofia, Bulgaria
🇨🇿University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno, Czechia
Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Oncopeptides AB
- Registration Number
- NCT04534322
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Beacon Cancer Care, Coeur d'Alene, Idaho, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 27
- Registration Number
- NCT04412707
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation - Glendale, Glendale, California, United States
🇧🇬Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Sofia, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment "Sveta Marina", Varna, Varna, Bulgaria
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
- Conditions
- AL Amyloidosis
- Interventions
- Drug: Melphalan-Flufenamide (Melflufen)
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 6
- Registration Number
- NCT04115956
- Locations
- 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇨🇿Fakultní Nemocnice Ostrava, Ostrava - Poruba, Czechia
🇫🇷Centre Hospitalier Universitaire de Limoges, Limoges, France
- Prev
- 1
- 2
- Next